bioAffinity Technologies, Inc. (NASDAQ:BIAFW – Get Free Report) passed below its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $0.24 and traded as low as $0.2180. bioAffinity Technologies shares last traded at $0.1970, with a volume of 702 shares traded.
bioAffinity Technologies Trading Down 19.5%
The stock has a fifty day moving average price of $0.30 and a two-hundred day moving average price of $0.24.
bioAffinity Technologies Company Profile
bioAffinity Technologies, Inc is a biotechnology company focused on developing noninvasive diagnostic tests and targeted cancer therapies. The company’s technology uses porphyrin compounds, which can bind to cancer cells and other biological targets, with the goal of improving the detection and treatment of cancer.
Its lead diagnostic product, CyPath Lung, is an investigational urine-based test designed to aid in the detection of lung cancer, including at earlier stages. The test uses a fluorescent porphyrin compound and flow cytometry to identify cancer-associated signals in urine.
Featured Articles
- Five stocks we like better than bioAffinity Technologies
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
